GLP ‐1 Receptor Agonists and Risk of Age‐Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation
Main finding · Incident AMDResult — go to the resultHazard ratio 0.82 95% CI 0.68–0.98Authors' conclusion
GLP-1RA use is associated with a reduced risk of incident AMD-statistically significant for unspecified AMD, with a potential trend towards a lower risk of nonexudative AMD-in obese adults without diabetes.
Study context
- Population
- Adults aged ≥ 60 years with obesity but without DM, TriNetX (January 2014-June 2025)
- Participants
- 157,880 matched patients
- Exposure
- GLP-1 RA initiation vs other weight-loss medications
- GLP-1RAn = 78,940
- Comparatorn = 78,940reference
- Outcome
- Incident AMD
- Follow-up
- Maximum 7-year observation window; median 1.11 years (IQR 1.48) GLP-1RA vs 2.56 years (IQR 3.89) comparator
Methodological details1:1 propensity score matching, TriNetX global health research network
- 1:1 propensity score matching
- TriNetX global health research network
Main finding
As reported in the abstract
Hazard ratio
0.82
95% CI 0.68–0.98
GLP-1RAvs Comparator
HR 0.82 (95% CI 0.68–0.98)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Unspecified AMD | 0.70 (0.52–0.93) | ||
| Nonexudative AMD | 0.78 (0.60–1.00) | P = 0.050 | |
| 0.512Hazard ratio (log scale) |
Subgroups (sex, age)
- Stronger effects in women and adults aged 60-69 years
- Exploratory
Original publication
GLP ‐1 Receptor Agonists and Risk of Age‐Related Macular Degeneration in Older Adults With Obesity: A Target Trial Emulation. Diabetes Obes Metab. Published 25 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →